Brian G. Engelhardt, M.D.

Associate Professor of Medicine, Hematology and Oncology

2665 TVC
Nashville
Tennessee
37232-5505

Hematological malignancies and stem cell transplantation

Clinical Information

Dr. Engelhardt is a medical oncologist who specializes in hematological malignancies and stem cell transplantation.

His clinical interests include: acute myeloid leukemia, stem cell transplantation, umbilical cord blood transplantation, Graft-versus-Host disease (GVHD), and metabolic complications following transplant.  More than 100,000 patients undergo stem cell transplantation annually throughout the world, with the primary indication being hematological malignancy. Patients undergoing stem cell transplantation are at risk for numerous acute and long-term complications including: graft-versus-host disease (GVHD), infectious complications, and new-onset metabolic disorders.  Many of these disease states are related to abnormalities in immune regulation and lymphocyte migration. Dr. Engelhardt has an ongoing program of unique and innovative research investigating tissue-homing characteristics of immune effector and suppressor cells to determine their role in complications of allogeneic stem cell transplantation.  His research has specifically focused on 1) the use of umbilical cord blood as an alternative donor source to minimize GVHD, 2) tissue-homing T cell subsets as predictors / biomarkers of GVHD outcomes, and 3) the physiology and immunology of glucose metabolism after transplant.  It is notable that this last line of research represents an entirely new field of study in stem cell transplantation which integrates transplant immunology with endocrinology.

Research Description

Dr. Engelhardt is a medical oncologist who specializes in hematological malignancies and stem cell transplantation.  His clinical interests include: acute myeloid leukemia, stem cell transplantation, umbilical cord blood transplantation, and Graft-versus-Host disease (GVHD).  Dr. Engelhardt is interested in developing new treatments for acute leukemia. He has ongoing clinical trials examining the use of single or double umbilical cord blood unit transplantation for patients with advanced hematological malignancies without a suitable matched related or unrelated donor.  His research interests also focus on the immune reconstitution and regulation following stem cell transplantation.  He is currently exploring the relationship between regulatory T cells and acute Graft-versus-Host disease after allogeneic stem cell transplantation.

Publications on PubMed.gov